Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2008

Calibrant and Armed Forces Institute of Pathology Ally to Discover and Develop Protein Biomarkers

  • Calibrant Biosystems inked a CRADA with the Armed Forces Institute of Pathology (AFIP) to use its Gemini™ proteomics platform in the discovery and development of protein biomarkers. The partners will first conduct research in the area of brain cancer.

    AFIP’s tissue microarray laboratory will produce standard and custom tissue microarrays according to Calibrant’s specifications. The company’s technologies will be used to evaluate and validate protein markers for a variety of major, unmet medical needs. Gemini provides the ability to comparatively map protein networks between different cell types within a single tissue section, according to the company.

    “Working in partnership with the AFIP via this CRADA offers an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples,” says Michael L. Salgaller, Ph.D., COO at Calibrant.

    “This collaboration should expedite the search for novel markers or sets of markers of disease, permitting more sensitive and targeted detection, diagnosis, and prognosis,” adds Satya Saxena, Ph.D., vp for research.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »